RxDoctor Payments Data

Angel Tejeda, MD

Nephrology · Hialeah, FLNPI 1710905914

Payments from drug & device makers

$4,069in general payments, 2019–2025

Across 150 payments — averaging $27.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Bayer$568
  • Mallinckrodt Hospital Products Inc.$391
  • Vifor Pharma, Inc.$316
  • Otsuka America Pharmaceutical, Inc.$289
  • Calliditas Therapeutics US Inc.$185
  • plus $635 from 8 others

What the payments were for

  • Food & beverage$3,94697%
  • Education$1223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,069 in reported general payments places this provider in the 65th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$23,343
Medicare patients
69
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol253$229,466
KerendiaFinerenone50$44,834
LokelmaSodium Zirconium Cyclosilicate33$24,687
VeltassaPatiromer Calcium Sorbitex23$21,313
JardianceEmpagliflozin19$19,906
Sevelamer Carbonate49$3,718
Calcium Acetate24$790
Nifedipine ErNifedipine21$438
Furosemide52$167
Atorvastatin Calcium19$90
Vitamin D2Ergocalciferol (Vitamin D2)22$86
Hydralazine Hcl19$77
Hydrochlorothiazide16$71
Amlodipine Besylate22$56
Allopurinol12$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,685$254,154286 claims
BayerKerendia$568$44,83450 claims
Boehringer IngelheimJardiance$115$19,90619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 756 nephrology providers in Florida.

Other nephrology in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →